CERENOME, INC. CNSY
Plus Therapeutics is a U.S. healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system ("CNS") cancers. CNSide Diagnostics, LLC ("CNSide Diagnostics") is our wholly owned subsidiary that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. In radiopharmaceuticals, our lead candidate, rhenium (186Re) obisbemeda, is designed specifically for CNS cancers including recurrent glioblastoma ("GBM"), leptomeningeal metastases ("LM"), and pediatric brain cancers ("PBC") by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery ("CED") and intraventricular brain (Ommaya reservoir) catheters. Our acquired radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere ("188RNL-BAM") is designed to treat many solid organ cancers including primary and secondary liver cancers by intra-arterial injection.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.2M | $5.8M | $4.9M | — | — | — | — | $1.0M | $2.7M | $4.7M |
| Cost of revenue | — | — | — | — | — | — | — | $1.1M | $1.3M | $2.7M |
| Gross profit | — | — | — | — | — | — | — | -$148.0K | $146.0K | $1.9M |
| R&D | $8.4M | $10.6M | $9.7M | $9.7M | — | $2.7M | $5.4M | $5.5M | $5.1M | $16.2M |
| SG&A | $12.1M | $9.9M | $8.5M | $10.2M | $6.9M | $6.4M | $5.3M | $5.6M | $6.7M | $8.6M |
| Total operating expenses | $20.5M | $20.5M | $18.2M | $19.9M | $12.5M | $9.9M | $10.7M | $11.7M | $14.8M | $28.4M |
| Operating income | -$15.3M | -$14.7M | -$13.3M | -$19.7M | -$12.5M | -$9.6M | -$3.7M | -$8.8M | -$11.1M | -$19.7M |
| Interest expense | $548.0K | $179.0K | $395.0K | $711.0K | $932.0K | $1.1M | $1.9M | $1.9M | $2.0M | $2.6M |
| Pre-tax income | -$22.4M | -$13.0M | -$13.3M | -$20.3M | -$13.4M | -$8.2M | -$10.9M | -$12.6M | -$22.7M | -$22.0M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$22.4M | -$13.0M | -$13.3M | -$20.3M | -$13.4M | -$8.2M | -$10.9M | -$12.6M | -$22.7M | -$22.0M |
| EPS, basic | -0.29 | -1.95 | -4.24 | -11.58 | -1.11 | — | — | — | — | — |
| EPS, diluted | -0.29 | -2.34 | -4.24 | -11.58 | -1.11 | -1.86 | -8.27 | -86.98 | -411.60 | -1.28 |
| Shares, diluted (wtd. avg.) | $77.8M | $7.7M | $3.1M | $1.8M | $12.1M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.3M | $76.0K | $8.6M | $18.1M | $18.4M | $8.3M | $17.6M | $5.3M | $9.6M | $12.6M |
| Short-term investments | $4.4M | $3.5M | — | — | — | — | — | — | — | — |
| Receivables | — | — | — | — | — | $0 | $1.2M | $178.0K | $145.0K | $1.2M |
| Inventory | — | — | — | — | — | — | $107.0K | $107.0K | $3.2M | $3.7M |
| Total current assets | $15.2M | $5.3M | $9.8M | $21.8M | $19.7M | $9.2M | $19.8M | $9.6M | $14.9M | $18.7M |
| Property, plant and equipment | $257.0K | $448.0K | $906.0K | $1.3M | $1.5M | $1.8M | $2.2M | $2.3M | $3.1M | $1.2M |
| Goodwill | $372.0K | $372.0K | $372.0K | $372.0K | $372.0K | $372.0K | $372.0K | $372.0K | $3.9M | $3.9M |
| Other intangibles | $333.0K | $469.0K | $42.0K | — | — | — | — | $6.0M | $7.2M | $8.4M |
| Total assets | $16.3M | $6.6M | $11.4M | $23.9M | $22.0M | $12.1M | $23.2M | $24.0M | $31.6M | $34.6M |
| Accounts payable | $3.3M | $9.5M | $4.8M | $8.4M | $2.6M | $789.0K | $327.0K | $721.0K | $1.3M | $1.3M |
| Short-term debt | — | — | $4.0M | $1.6M | $1.6M | $6.3M | $11.1M | $14.2M | $13.6M | $6.6M |
| Total current liabilities | $12.3M | $15.6M | $10.7M | $11.9M | $5.9M | $8.5M | $14.5M | $17.6M | $18.4M | $12.5M |
| Long-term debt | — | — | — | $3.8M | $5.0M | — | — | — | — | — |
| Total liabilities | $12.3M | $15.6M | $12.7M | $17.4M | $11.1M | $9.1M | $22.1M | $18.8M | $18.6M | $23.6M |
| Retained earnings | -$515.9M | -$493.5M | -$480.5M | -$467.2M | -$446.9M | -$433.5M | -$425.3M | -$414.4M | -$401.7M | -$379.1M |
| Total equity | $4.0M | -$8.9M | -$1.3M | $6.4M | $10.8M | $3.0M | $1.2M | $5.2M | $13.0M | $11.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.8M | -$10.6M | -$12.9M | -$13.0M | -$10.3M | -$8.4M | -$5.9M | -$12.0M | -$18.1M | -$19.5M |
| Depreciation and amortisation | $445.0K | $872.0K | $628.0K | $619.0K | $395.0K | $366.0K | $896.0K | $2.0M | $2.2M | $1.2M |
| Stock-based compensation | $1.5M | $550.0K | $569.0K | $606.0K | $606.0K | $247.0K | $127.0K | $355.0K | $753.0K | $1.1M |
| Capital expenditure | $67.0K | $146.0K | $160.0K | — | — | — | $67.0K | $133.0K | $295.0K | $67.0K |
| Investing cash flow | -$854.0K | -$4.1M | -$160.0K | -$759.0K | -$82.0K | -$493.0K | $5.6M | -$133.0K | -$1.4M | $64.0K |
| Financing cash flow | $30.3M | $6.2M | $3.4M | $13.5M | $20.4M | -$319.0K | $12.6M | $7.2M | $16.8M | $17.6M |
| Buybacks | — | $374.0K | $126.0K | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-104258.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $116.27B | 36.1x | 11.2% |
| MMM | 3M CO | $86.93B | 28.1x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $69.27B | 24.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $50.32B | 31.7x | 8.2% |
| DXCM | DEXCOM INC | $33.17B | 42.1x | 15.6% |
| RMD | RESMED INC | $32.94B | 21.9x | 9.9% |
| MDLN | Medline Inc. | $31.35B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $23.93B | 50.1x | 6.3% |